Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial

Analysis of the RE-LY trial (n=18,107) found that systolic blood pressure (SBP) >140 mmHg and <120 mmHg was associated with increased all-cause death vs SBP 120–130 mmHg. Low SBP was also associated with increased bleeding.


European Heart Journal